Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГУ Институт неврологии, психиатрии и наркологии НАМН Украины, Харьков, Украина
Список исп. литературыСкрыть список 1. Gaebel W, Becker T, Janssen B et al. EPA guidance o the quality of mental health services. Eur Psychiat 2012; 27 (2): 87–113. 2. McGory PD, Killackey A, Yuang E. Early intervention in psychosis: conspectus, evidence and future directions. J World Psychiat 2008; 7 (3): 148–57. 3. Bugarski-Kirola D. Future prospects in the treatment of negative symptoms. European archives of psychiatry. Clin Neuroscience 2013; 263 (1): 23. 4. Galderisi S. Improving schizophrenia outcome. European psychiatry. J Europ Psychiat Associat. 21st European Congress of Psychiatry, 6–9 April, 2013. Nice, France. Topic 321. State of the Art: Improving Schizophrenia Outcome. Abstr. 2995. 5. Gaebel W. Mainetense treatment with risperidone or low-dose haloperidol in fist-episode schizophrenia. One-year result of a randomized controlled trial within German Research Network on Schizophrenia. J Clin Psychiat 2007; 68 (11): 1763–74. 6. Galderisi S. Negative symptoms in schizophrenia: prevalence and impact on functional outcome. European archives of psychiatry. Clin Neuroscience 2013; 263 (1): 22. 7. Berck M, Dean O. Novel mechanisms to improve negative symptoms – initial success and new directions. Europ Neuropsychopharmacol 2013; 23 (2): 132. 8. Elanjithara T, Winton-Brown T, McGuire P. Interruption of anti-psychotic treatment of first episode psychosis associated with a five-fold increased risk of relapse. European Psychiatry. J Europ Psychiatr Association. 21st European Congress of Psychiatry, 6–9 April, 2013. Nice, France. Schizophrenia 2013; 69. Abstr. 1414. 9. Fleischhacker WW, Sanchez R, Jin N et al. Personal and social performance in schizophrenia: double-blind, non-inferiority study of one monthly vs oral aripiprazole. Europ Neuropsychopharmacol 2013; 23 (2): 474. 10. Schreiner A, Svensson A, Wapenaar R et al. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: a prospective one-year non-interventional study (INORS). European Psychiatry. J Europ Psychiatr Association. 21st European Congress of Psychiatry, 6–9 April, 2013. Nice, France. Topic 69. Schizophrenia. Abstr. 1736. 11. Guo X, Zhai J, Liu Z et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized 1-year study. Arch Gen Psychiat 2010; 67: 895–904. 12. Rybakowski JK. Extrapyramidal and metabolic side effect of antipsychotic treatment: data from EUFEST. Europ Neuropsychopharmacol 2013; 23 (2): 126. 13. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80 (1): 19–32. 14. Fleischhacker WW, Siu CO, Boden R et al. EUFEST Study Group. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analyzed from the European First-Episode Schizophrenia Trial. Internation J Neuropsychopharmacol 2013; 16 (5): 987–95